Literature DB >> 17217615

Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants.

Jayaprakash Aravindakshan1, Xinlei Chen, M Ram Sairam.   

Abstract

Ovarian cancer is a deadly disease with long latency. To understand the consequences of loss of follicle-stimulating hormone receptor (FSH-R) signaling and to explore why the atrophic and anovulatory ovaries of follitropin receptor knockout (FORKO) mice develop different types of ovarian tumors, including serous papillary epithelial adenoma later in life, we used mRNA expression profiling to gain a comprehensive view of misregulated genes. Using real-time quantitative reverse transcription-polymerase chain reaction, protein analysis, and cellular localization, we show, for the first time, in vivo evidence that, in the absence of FSH-R signaling, claudin-3, claudin-4, and claudin-11 are selectively upregulated, whereas claudin-1 decreases in ovarian surface epithelium and tumors in comparison to wild type. In vitro experiments using a mouse ovarian surface epithelial cell line derived from wild-type females reveal direct hormonal influence on claudin proteins. Although recent studies suggest that cell junction proteins are differentially expressed in ovarian tumors in women, the etiology of such changes remains unclear. Our results suggest an altered hormonal environment resulting from FSH-R loss as a cause of early changes in tight junction proteins that predispose the ovary to late-onset tumors that occur with aging. More importantly, this study identifies claudin-11 overexpression in mouse ovarian serous cystadenoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17217615      PMCID: PMC1783714          DOI: 10.1593/neo.06529

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  33 in total

Review 1.  Origins and molecular pathology of ovarian cancer.

Authors:  Debra A Bell
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

Review 2.  Endogenous hormones and ovarian cancer: epidemiology and current hypotheses.

Authors:  Annekatrin Lukanova; Rudolf Kaaks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-01       Impact factor: 4.254

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 4.  Claudin proteins in human cancer: promising new targets for diagnosis and therapy.

Authors:  Patrice J Morin
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

5.  Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase A pathway.

Authors:  Yuen Lam Pon; Nelly Auersperg; Alice S T Wong
Journal:  J Biol Chem       Date:  2005-02-08       Impact factor: 5.157

6.  Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

Authors:  Denise C Connolly; Rudi Bao; Alexander Yu Nikitin; Kasie C Stephens; Timothy W Poole; Xiang Hua; Skye S Harris; Barbara C Vanderhyden; Thomas C Hamilton
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

7.  Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity.

Authors:  Rachana Agarwal; Theresa D'Souza; Patrice J Morin
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

8.  Formation and barrier function of tight junctions in human ovarian surface epithelium.

Authors:  Yihong Zhu; Julia Maric; Mikael Nilsson; Mats Brännström; P-O Janson; Karin Sundfeldt
Journal:  Biol Reprod       Date:  2004-02-18       Impact factor: 4.285

9.  Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.

Authors:  Leticia B A Rangel; Rachana Agarwal; Theresa D'Souza; Ellen S Pizer; Piero L Alò; Wayne D Lancaster; Lucie Gregoire; Donald R Schwartz; Kathleen R Cho; Patrice J Morin
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

10.  Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study.

Authors:  Murray B Resnick; Tamako Konkin; Justin Routhier; Edmond Sabo; Victor E Pricolo
Journal:  Mod Pathol       Date:  2005-04       Impact factor: 7.842

View more
  6 in total

1.  Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.

Authors:  Babak Litkouhi; Joseph Kwong; Chun-Min Lo; James G Smedley; Bruce A McClane; Margarita Aponte; Zhijian Gao; Jennifer L Sarno; Jennifer Hinners; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

2.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

3.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 4.  Claudin and ovarian cancer.

Authors:  Chinmoy K Bose; Ashis Mukhopadhyay
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

5.  Early alterations in ovarian surface epithelial cells and induction of ovarian epithelial tumors triggered by loss of FSH receptor.

Authors:  Xinlei Chen; Jayaprakash Aravindakshan; Yinzhi Yang; M Ram Sairam
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

6.  β-catenin/Tcf-signaling appears to establish the murine ovarian surface epithelium (OSE) and remains active in selected postnatal OSE cells.

Authors:  Macalister Usongo; Riaz Farookhi
Journal:  BMC Dev Biol       Date:  2012-06-08       Impact factor: 1.978

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.